Growth & profitability
- Revenue has grown 34.5% per year over the past 5 years.
- Operating margin has expanded, at 11.2% in the latest year.
Financial health
- Total debt has grown slower than revenue (-46.2% vs 34.5% per year).
VCYT Financials Veracyte, Inc.
10 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $517M | $66M | 70.1% | 11.2% | $127M | — | $363M |
| 2024 | $446M | $24M | 66.9% | 3.6% | $64M | — | $239M |
| 2023 | $361M | -$74M | 63.6% | -23.8% | $34M | — | $216M |
| 2022 | $297M | -$37M | 59.2% | -13.9% | -$1M | — | $154M |
| 2021 | $220M | -$76M | 0.0% | -37.3% | -$37M | $1M | $173M |
| 2020 | $117M | -$35M | 0.0% | -30.1% | -$13M | $810000 | $349M |
| 2019 | $120M | -$13M | 70.0% | -12.6% | -$6M | $694000 | $159M |
| 2018 | $92M | -$23M | 64.0% | -24.2% | -$15M | $25M | $78M |
| 2017 | $72M | — | 60.8% | -36.9% | -$26M | $25M | $34M |
| 2016 | $65M | — | 60.9% | -44.3% | -$32M | $25M | $59M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $139M | $29M | 72.7% | 16.3% | $32M | — | $263M |
| Dec '25 | $141M | $41M | 72.5% | 26.4% | $49M | — | $363M |
| Sep '25 | $132M | $19M | 69.2% | 17.4% | $42M | — | $316M |
| Jun '25 | $130M | -$980000 | 69.0% | -4.0% | $32M | — | $219M |
| Mar '25 | $114M | $7M | 69.5% | 2.5% | $4M | — | $186M |
| Dec '24 | $119M | $5M | 66.4% | 3.5% | $20M | — | $239M |
| Sep '24 | $116M | $15M | 68.2% | 10.4% | $28M | — | $274M |
| Jun '24 | $114M | $6M | 68.1% | 4.0% | $27M | — | $236M |
| Mar '24 | $97M | -$2M | 64.5% | -4.8% | -$11M | — | $209M |
| Dec '23 | $98M | -$28M | 66.0% | -36.2% | $13M | — | $216M |
| Sep '23 | $90M | -$30M | 64.0% | -35.2% | $11M | — | $202M |
| Jun '23 | $90M | -$8M | 61.8% | -8.9% | $13M | — | $191M |
| Mar '23 | $82M | -$8M | 0.0% | -12.7% | -$3M | — | $178M |
| Dec '22 | $80M | -$4M | 0.0% | -6.7% | $8M | — | $154M |
| Sep '22 | $76M | -$9M | 0.0% | -12.8% | $5M | — | $170M |
| Jun '22 | $73M | -$10M | 0.0% | -14.7% | -$3M | — | $153M |
| Mar '22 | $68M | -$14M | 0.0% | -22.5% | -$11M | — | $164M |
| Dec '21 | $67M | -$11M | 0.0% | -18.3% | $8M | $1M | $173M |
| Sep '21 | $60M | -$14M | 0.0% | -27.6% | -$3M | $1M | $164M |
| Jun '21 | $55M | -$9M | 0.0% | -13.6% | $360000 | $917000 | $328M |
Valuation over time
How the market has priced VCYT against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 131.1× (Dec '24) to 70.3× (Jun '26).
- The price-to-sales ratio has risen from 6.0× (Mar '23) to 9.0× (Jun '26).
P/E
P/S
Frequently asked questions
Is VCYT growing its revenue and profit?
Over the past 5 years, Veracyte, Inc.'s revenue has grown 34.5% per year. These are computed facts, not advice.
How much debt does VCYT have?
As of FY2025, Veracyte, Inc. reported — of total debt against $363M of cash.
What is VCYT's profit margin?
In FY2025, gross margin was 70.1%, operating margin 11.2%, and net margin 12.8%.
What is VCYT's P/E ratio?
As of Jun '26, Veracyte, Inc. traded at a price-to-earnings ratio of about 70.3× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.